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ABSTRACT
The effects of albumin and human serum on the
pharmacodynamics of faropenem were studied.
The protein binding of faropenem was 91–95%,
corresponding to the increase in MICs for Haemo-
philus influenzae in broth supplemented with
albumin. Time-kill experiments in albumin-con-
taining medium and in inactivated human serum
50% v ⁄ v showed that much higher drug concen-
trations were needed to achieve a bactericidal
effect than were needed in broth. Active human
serum alone exerted a strain-dependent bacteri-
cidal effect. It was concluded that it is the free
fraction of faropenem in serum that has antibac-
terial activity against H. influenzae.
Keywords Antimicrobial effect, faropenem, Haemo-
philus influenzae, pharmacodynamics, protein binding,
serum
Original Submission: 11 January 2004; Revised Sub-
mission: 28 March 2004; Accepted: 30 March 2004
Clin Microbiol Infect 2004; 10: 934–937
10.1111/j.1469-0691.2004.00977.x
Faropenem is a synthetic antibiotic of the penem
group that is no longer under clinical develop-
ment, but which has antibacterial activity
against Gram-positive and Gram-negative bac-
teria, including strains producing ß-lactamase
[1,2]. The plasma protein binding of faropenem
is c. 90%, which affects its antibacterial activity
[3]. The aim of this study was to examine the
influence of human albumin and serum on the
pharmacodynamics of faropenem against
Haemophilus influenzae.
Ten H. influenzae strains were studied, inclu-
ding two b-lactamase-positive strains (LH 2803
and 405298), obtained from Glaxo SmithKline
Pharmaceuticals (Welwyn Garden City, UK), and
eight clinical isolates (four b-lactamase-positive)
obtained from the Department of Clinical Micro-
biology Laboratory, Uppsala University Hospital,
Sweden. Pooled human serum was obtained from
the same department and was heat-inactivated at
56C for 30 min. Mueller–Hinton broth (Difco
Laboratories, Detroit, MI, USA) supplemented
with haemin 30 mg ⁄L (Sigma, St Louis, MO,
USA) and IsoVitaleX (Becton Dickinson, Cockeys-
ville, MD, USA) 1% v ⁄ v was used throughout the
study.
Faropenem was provided by Bayer AG (Wup-
pertal, Germany) and dissolved in sterile distilled
water before each experiment. MICs were deter-
mined in broth with and without human albumin
(fraction V; Sigma) 40 g ⁄L by a macrodilution
technique with two-fold serial dilutions. Bacteria
from 6-h cultures were diluted to give a final
inoculum of 5 · 105 CFU ⁄mL and incubated at
35C in CO2 5% v ⁄ v for 20 h. The MIC was
defined as the lowest antibiotic concentration
with no visible growth.
Protein binding was determined by an ultrafil-
tration method in four different protein solutions:
human albumin 40 g ⁄L and 20 g ⁄L, and active
and inactivated human serum 50% v ⁄v. Plastic
tubes were saturated with CO2. Faropenem was
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added to 2 mL of the protein-containing solution
in cellophane dialysis tubing membranes (Union
Carbide Corporation, Houston, TX, USA) to
obtain an antibiotic concentration of 2 mg ⁄L.
The dialysis membranes were placed in plastic
tubes and centrifuged at 507 g for 5 min, and then
transferred to new plastic tubes and centrifuged
at 757 g for 1 h. The faropenem concentration was
determined in the initial samples and in the
filtrates after the last centrifugation step by a
microbiological agar diffusion method with Bacil-
lus stearothermophilus ATCC 3032 as the test
organism. A standardised inoculum of spore
suspension was mixed with nutrient agar (Difco)
and poured into plates. Antibiotic standards of
faropenem and the samples were placed in agar
wells. The assays were made in triplicate and
incubated at 56C overnight.
The pharmacodynamics of faropenem were
studied in media with and without human
albumin 20 g ⁄L, corresponding to the albumin
content in interstitial fluid. H. influenzae LH 2803
was exposed to faropenem at concentrations of 2,
5, 10, 20 and 50 times the MIC determined in
broth. Growth controls were included. Samples
were withdrawn for viable counts after 0, 3, 6 and
24 h and seeded in appropriate dilutions on
haematin agar (Columbia agar base (Difco) con-
taining lysed horse blood 5% v ⁄ v). The plates
were incubated at 35C in CO2 5% v ⁄v overnight,
and colonies were counted. All experiments were
performed in duplicate.
Strain 405298 and a b-lactamase-positive clin-
ical isolate (2045) were exposed to faropenem
12 mg ⁄L, corresponding approximately to the
Cmax (total concentration) obtained in patients
following administration of 300 mg of faropenem
daloxate. Two different media were compared,
namely broth and broth containing inactivated
human serum 50% v ⁄ v. Viable counts were made
after 0, 2, 4, 8, 12 and 24 h as described above.
To study the bactericidal effect of active serum,
seven H. influenzae strains with the ability to grow
in active serum were exposed to faropenem at 3, 6
and 12 mg ⁄L in broth containing active human
serum 50% v ⁄v. Growth controls were included,
and viable counts were made after 0, 4, 8 and 24 h
as described above.
Protein binding of faropenem was found to be
91% and 95% in human albumin 20 g ⁄L and
40 g ⁄L, respectively, and 92–93% in inactivated
and active human serum 50% v ⁄ v.
MICs in broth cultures were 0.125–2 mg ⁄L for
the ten H. influenzae strains, and increased 4–16-
fold to 0.5–8 mg ⁄L in media containing albumin
40 g ⁄L. Using the formula (1 ) (A ⁄B)) · 100,
where A is the MIC in broth, and B is the MIC
in broth supplemented with albumin 40 g ⁄L, the
increase in MIC corresponded to a mean protein
binding of 89% (range 75–94%).
A bactericidal effect of faropenem was noted at
2 · MIC in broth (Fig. 1), but a similar reduction
could not be achieved, even with 50 · MIC, in the
presence of human albumin 20 g ⁄L. A bacterio-
static effect was seen with albumin at a concen-
tration of 10 · MIC, corresponding to a free
concentration of c. 1 · MIC.
Cultures in inactivated human serum 50% v ⁄ v
and faropenem 12 mg ⁄L showed a reduction in
viable count of 4.3 logs after 24 h for strain 2045
(MIC 0.5 mg ⁄L), whereas strain 405298 (MIC
2 mg ⁄L) was much less affected. Regrowth of
strain 405298 occurred after 12 h and 24 h (Fig. 2).
In broth, both strainswere reducedby4–5 logs after
24 h (Fig. 2). In active human serum 50% v ⁄ v with
faropenem 3 mg ⁄L (free concentration of
0.3 mg ⁄L), the counts for five of the seven strains
were below the limit of detection after 24 h.
Regrowth of two strains occurred. At higher con-
centrations (6 and 12 mg ⁄L), the viable counts of all
seven strains were reduced by 5 logs after 24 h.
Only the free (non-protein-bound) fraction of
an antibiotic exerts antibacterial activity and
is able to diffuse rapidly from plasma to the
extravascular compartments where most bacterial
infections are located [4–7]. Despite this, the
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Fig. 1. The effects of different concentrations of faropenem
against Haemophilus influenzae strain LH 2803. The solid
lines represent media containing human albumin 20 g ⁄L
and the dotted lines represent broth cultures. Results
shown are the means of three experiments.
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influence of protein binding on antibacterial
efficacy is still controversial. Much of this confu-
sion is caused by the fact that the magnitude of
the pharmacodynamic index needed for an opti-
mal antibacterial effect is still unclear. The good
efficacy of some antibiotics with high protein
binding is explained by the fact that the free
concentrations are sufficient to reach the pharma-
cokinetic ⁄pharmacodynamic indices (e.g., time
above MIC, area under the curve (AUC) ⁄MIC)
that are needed for an antibacterial effect [8–11].
However, for some protein-bound drugs, sub-
optimal free concentrations in relation to MICs
may lead to treatment failure [12].
The results in this study show that MIC values
increase proportionally to the level of protein
binding, which is in agreement with previous
studies [3,13]. It was also apparent in the killing
experiments in medium containing albumin
(Fig. 1) that free concentrations of antibiotic above
the MIC were needed to achieve an antibacterial
effect. In cultures containing inactivated human
serum 50% v ⁄ v, the free fraction of faropenem
was c. 1.2 mg ⁄L. This concentration was sufficient
to effectively kill strain 2045 (MIC 0.5 mg ⁄L), but
was just below the MIC (2 mg ⁄L) for strain
405298, so that exposure to sub-inhibitory con-
centrations gave a temporary reduction in bacter-
ial counts followed by regrowth. However, when
strains of H. influenzaewere exposed to faropenem
in active serum, a bactericidal effect was noted
even in the presence of low (sub-MIC) free
faropenem concentrations. The mechanisms be-
hind this synergic effect are not clear and require
further investigation. Overall, it was concluded
that the pharmacodynamic activity of faropenem
in the presence of albumin or inactivated serum
suggests clearly that it is the free fraction of
faropenem that correlates with its antibacterial
effect.
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Fig. 2. Killing effects of faropenem 12 mg ⁄L against Hae-
mophilus influenzae strains 2045 and 405298. The solid lines
represent the culture medium with inactivated human
serum 50% v ⁄ v and the dotted lines represent broth.
Growth controls from the medium with serum are inclu-
ded. Bars indicate the standard deviation observed with
three experiments.
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ABSTRACT
DNA was extracted with a modified Qiagen DNA
Mini Kit method from 20 clinical samples and was
amplified by PCR using specific primers for the
T. gondii B1 gene. T. gondii was detected correctly
in 18 of the 20 clinical samples in < 5 h, with a
detection limit of two parasites ⁄ sample. The
results were in good agreement with those
obtained by a more complicated and time-con-
suming procedure involving two-step nested PCR
and either liquid hybridisation or colorimetric
detection using internal probes.
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The diagnosis of toxoplasmosis is based mainly
on the isolation and cultivation of parasite cells,
or on detection by serology, but these methods
are rather insensitive and time-consuming.
Nested PCR and PCR-ELISA have been used to
complement serodiagnosis [1–4], but although
these approaches are comparatively sensitive,
they are still complicated and time-consuming
[5–7]. In the present report, a simple PCR method
to detect Toxoplasma gondii-specific DNA directly
from clinical samples is described. The method
can be applied to amniotic fluid, vitreous fluid,
cerebrospinal fluid, blood samples and tissue
specimens.
The B1 gene of T. gondii is a 35-fold repetitive
gene, with 2214 nucleotides in each repeat, and is
highly conserved among Toxoplasma strains [8,9].
Primers Tg1 (5¢-AAAAATGTGGGAATGAAA-
GAG-3¢) and Tg2 (5¢-ACGAATCAACGGAACTG
TAAT-3¢) were designed and tested for specificity
in the BLASTN data base (http://www.ncbi.nlm.-
nih.gov/BLAST) and were predicted to be 100%
specific for the B1 gene. PCR with these primers
amplified a 469-bp DNA fragment of the B1 gene.
The PCR control primers used were b1 (5¢-AC-
CACCAACTTCATCCACGTTCACC-5¢) and b2
(5-CTTCTGACACAACTGTGTTCACTAGC-3¢);
these amplified a 140-bp DNA fragment of the
human b-globin gene [10]. Both reactions were
run simultaneously with the same temperature
protocol in parallel tubes in the same PCR
machine.
Twenty clinical samples, consisting of eight
amniotic fluid samples, two cerebrospinal fluid
samples, four vitreous fluid samples and six
tissue samples, were received from the Depart-
ment of Virology, Helsinki University Central
Hospital, Helsinki, Finland, and the Department
of Microbiology, Ullevaal University Hospital,
Oslo, Norway. All the samples were coded upon
receipt. The tissue samples were collected in
physiological saline in sterile tubes and stored at
) 70C immediately upon arrival until analysed.
The liquid samples were transferred to 2-mL
sterile microcentrifuge tubes and centrifuged at
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